title: [18F]fluorothymidine PET imaging in the diagnosis of leptomeningeal involvement with diffuse large B-cell lymphoma.
abstract: The diagnosis of leptomeningeal carcinomatosis remains difficult despite improvement in central nervous system (CNS) imaging and cytologic examination of the cerebral spinal fluid. False-negative results are common, providing obstacles in assessing both prophylactic and therapeutic efforts. As a result of increased survival of patients with a variety of systemic neoplasms it is likely that central nervous involvement will need to be addressed more often. This article presents a patient with a diffuse large B-cell lymphoma with polymorphic features. Imaging using 18F-labeled fluorodeoxythymidine (FLT) proved useful in demonstrating both parenchymal and leptomeningeal CNS involvement. The potential for FLT to identify proliferative tissue may make it uniquely suitable for detection of CNS malignant disease.
authors: Section of Hematology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. jennifer-holter@ouhsc.edu
authors: Jennifer L
authors: JL
authors: Holter
authors: Kristin
authors: K
authors: Thorp
authors: M Leann
authors: ML
authors: Smith
authors: Katarzyna
authors: K
authors: Kedzierska
authors: Kar-Ming A
authors: KM
authors: Fung
authors: George
authors: G
authors: Chacko
authors: Karen
authors: K
authors: Swisher
authors: Robert
authors: R
authors: Epstein
authors: Mary K
authors: MK
authors: Gumerlock
mesh_terms: D015224:Dideoxynucleosides; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging*; D008577:Meningeal Neoplasms / Q000000981:diagnostic imaging*; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals
chemical_list: D015224:Dideoxynucleosides; D019275:Radiopharmaceuticals; C002854:alovudine